GCAL® plasma and serum calprotectin in the ICU - WorldLab-EuroMedLab

19. May 2023 | 6 min read

GCAL® plasma and serum calprotectin in the ICU - WorldLab-EuroMedLab

Posters: GCAL®'s role in critically ill patients in the ICU 

Gentian’s GCAL® plasma and serum calprotectin immunoassay has been used in studies presented through posters at WorldLab-EuroMedLab. 

If you want to learn more about GCAL® in the ICU please visit Gentian’s booth 129.

You can access the abstracts here.

Posters:

Usefulness of serum calprotectin for predicting mortality in critically ill patients with sepsis (P1944)*

The results from a study at Hospital Universitario Santa Lucía, Cartagena, Spain, and Hospital Ibermutuamur, Murcia, Spain, indicate that serial calprotectin, in combination with SOFA score, could be used for risk stratification of septic ICU patients, and that GCAL® availability on high throughput platforms can contribute to optimal treatment decisions related to care of severely ill patients.

Health economic impact of use of GCAL® calprotectin immunoassay for early detection of infection in ICU patients (P1963)**

The base-case scenario in this study identified GCAL® Calprotectin Immunoassay as cost-effective for a patient cohort presenting in a Swedish ICU. Compared to the comparators, GCAL® saves total costs, reduces the mean duration of in-patient care, and reduces in-hospital mortality in those patients. In the sensitivity analysis, when key model inputs are varied, GCAL® Calprotectin Immunoassay remains the dominant option.

 

Gentian at EuroMedLab2023 - plasma and serum calprotectin

 

Calprotectin in severe events in infections

Calprotectin is a well described biomarker with several applications in bacterial infections. It can differentiate between bacterial and viral infection1-3 and distinguish sterile inflammation, such as trauma4. This allows for more accurate and effective use of antibiotics. Early and rapid kinetics of calprotectin in bacterial infections5,10, enable it to predict the need for antibiotics before onset of clinical symptoms5. This early detection can lead to significant cost savings and improved patient outcomes11. Elevated levels of calprotectin are also a valuable risk marker for severe events such as sepsis, septic shock, and mortality3,4,6-9 and improve classical risk scoring9.

Early detection and risk stratification can thereby help to identify patients at risk for deterioration and guide decisions on course of treatment or necessary transfer of patients to ICU12.

 

Gentian at EuroMedLab 2023 - plasma and serum calprotectin

 

Gentian Calprotectin GCAL® Immunoassay - early access to accurate results

GCAL® can be used for early detection and assessment of the inflammatory response to severe infections, where it is critical to get access to the results as soon as possible. Since GCAL® is a Particle-Enhanced Turbidimetric Immunoassay (PETIA), the assay is rapidly performed in only 10 minutes. It is available on a wide range of clinical chemistry platforms. The assay is IVDR certified.

 

Get in touch with Gentian

Interested in GCAL®? Want to know more? Meet us at WorldLab-EuroMedLab. Book a meeting by sending an email to marketing@gentian.com or fill out the form below:

 

Gentian Diagnostic Brochure

 

References:

  1. Havelka A et al. Scientific reports. 2020;10(1):4208-.
  2. Siljan WW et al. ERJ Open Res. 2019;5(1).
  3. Bartáková E et al. Diagn Microbiol Infect Dis. 2019;93(3):219-26.
  4. Larsson A et al. Scandinavian Journal of Clinical and Laboratory Investigation. 2019:1-6.
  5. Jonsson N et al. Crit Care Resusc. 2017;19(3):205-13.
  6. Gao S et al. Am J Emerg Med. 2015;33(9):1278-82.
  7. Parke Å et al. Critical Care. 2020;24(1):P477.
  8. Wirtz TH et al. Diagnostics (Basel). 2020;10(11):990.
  9. Dubois C et al. Scientific Reports. 2019;9(1).
  10. Fullerton J et al. Critical Care. 2020;24(1):P474.
  11. Havelka AL, M.; Hultström, M.; Larsson, A., editor Health economic impact of use of GCAL® calprotectin immunoassay for early detection of infection in intensive care patients International Symposium on Intensive Care and Emergency Medicine (ISICEM) meeting; 2023; Brussels.
  12. Parke Å et al. BMC Emerg Med. 2023;23(1):16.

 

* L. García De Guadiana-Romualdo3, L. Albert Botella4, M.D. Albaladejo-Otón3, Á. Puche Candel3, R. Jiménez Sánchez2, P. Conesa Zamora3, A. Havelka1

1) Gentian AS, Moss, Norway 2) Intensive Care Unit, Hospital Universitario Santa Lucía, Cartagena 3) Laboratory Medicine Department, Hospital Universitario Santa Lucía, Cartagena 4) Laboratory Medicine Department. Hospital Ibermutuamur, Murcia

** A. Havelka4 , M. Hultström2 , M. Lipcsey3 , A. Larsson1

1) Department of Medical Sciences, Clinical Chemistry, University Hospital, Uppsala, Sweden 2) Department of Surgical Sciences, Anesthesiology, Uppsala University, Uppsala, Sweden 3) Department of Surgical Sciences, Anesthesiology, Uppsala University, Uppsala, Sweden, 4) Gentian AS, Moss, Norway

 

CE bw

 

You may also read


Production assistant - HQ based in Moss, Norway

May 13, 2024

Production assistant - HQ based in Moss, Norway

Would you like to contribute to our ability to meet the internationally increasing demand for our products?..

Application Sales Specialist (US based) 

May 13, 2024

Application Sales Specialist (US based) 

Join Gentian: Application Sales Specialist (US based) We are looking for a new colleague in the position of..

Discussing cystatin C @ Spring Clinical Meetings 2024

May 08, 2024

Discussing cystatin C @ Spring Clinical Meetings 2024

Spring Clinical Meetings (SCM) is a great occasion for renal health care providers to get insights to..